Physician profile
Conrad H Benoit
NPI 1629059985
$2,208.67
in general payments reported to CMS, 2019-2025
24 companies · $840 in 2025
The $840 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.75 · 2020: $244 · 2021: $206 · 2022: $204 · 2023: $200 · 2024: $484 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.31 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $339.76 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $267.80 | 2024 | Evenity, Prolia |
| Pfizer INC. | $177.28 | 2020-2025 | |
| Glaxosmithkline, LLC. | $132.09 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.29 | 2021-2024 | Xifaxan |
| Abbvie INC. | $117.43 | 2023-2024 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $79.55 | 2025 | Mounjaro, Zepbound |
| Vanda Pharmaceuticals INC. | $68.24 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.96 | 2019-2022 | |
| Bausch Health US, LLC | $52.26 | 2022 | |
| Phathom Pharmaceuticals, INC. | $47.61 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $43.79 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $40.49 | 2022-2023 | Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $38.45 | 2023-2024 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29.91 | 2020 | |
| Rgh Enterprises LLC | $25.55 | 2025 | |
| Neuronetics, INC. | $22.63 | 2025 | Neurostar Tms Therapy System |
| Janssen Pharmaceuticals, INC | $21.19 | 2021 | |
| Mylan Specialty L.P. | $21.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.79 | 2021 | |
| Lucid Diagnostics INC. | $18.95 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.74 | 2021 | |
| Alexion Pharmaceuticals, INC. | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conrad Benoit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.